Research Delta | Atripla

Atripla - (600mg; 200mg; 300mg Tablet oral)

Generic Name	Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate	Innovator	Gilead
Dosage	600mg; 200mg; 300mg Tablet oral	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	More Than 5	Tentative Approvals	Less Than 5
Final Approvals	More Than 5	Generic Launches	Less Than 5
Indication	Indicated as a complete regimen or in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 40 kg.
Complexities	Yes

Executive Summary

**** *** *** ***** ** **** **** ** **** ******* ******* ******** ** *** *, ****, ******* ******** ** *** *, **** *** *** ************ *********. ***** **** ******** *** **** ** ******* ******* ***. *******, *******, *******, ******* ******** ** *** **, **** **** *** ********* *****. ** ****** **** **** **** *** ******* ******* *** **** *** ****** ** ******* ******** ****** *** ********** ****. **** ***** *** ******* ** ****'* *********** ******* *********. ******* ***** **** *** ****** ******* * ********** *** ***** ** ***** *** *** *****, *** ********* ** ******** **, ******* ***** ** ******** ****** ****. **** ***** ***** ****, ***** ***** **** ** **** ******* '*** *** '*** *** *** ************ *********. ********** *** ******* **** ***** ** **** ***** ** ****** ***** ** ****** * ****** ***** **** . ******* ***** **** ******** ********* ********, *** ***** ** ** ****** ** **** ** ** ***** **** ***** ***** **** ***** * **** *** *** ***** ****** ******* *** ****** ***** ****. **** ********* **** ********* ******** ***** ******.

Patent Status

Atripla	Patent 1	Patent 2	Patent 3	Patent 4	Patent 5	Patent 6	Patent 7	Patent 8	Patent 9	Patent 10	Patent 11	Patent 12	Patent 13	Patent 14	Patent 15	Patent 16	Patent 17	Patent 18
****	*******	*******	*******	*******	*******	*******	*******	*******	*******	*******	*******	*******	*******	*******	*******	*******	*******	*******
*****	*******	*******	*******	*******	*******	*******	*******	*******	*******	*******	*******	*******	*******	*******	*******	*******	*******	*******
*********	* *******	* *******	* *******	* *******	* *******	* *******	* *******	* *******	* *******	*******	*******	*******	*******	*******	*******	*******	*******	*******

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
****	* \ *	**** , ***	*******	********	* , **
*****	\	* , ****	*******	****	*** * ** *********
*********	\	* *******	* *******	********	****** * , ****

Chronology Of Events

***** *, **** : **** ******** ****** ***** *** ****** ****** **** ******* *** ****** *** & *** & ****** ***** * **** ******* **** ****** ** **** ** ******** ***** ** ******** ******** ** *******.
*** **, **** : ***** *** ********* ********, ********* ** ***** ***** ***** **** *** ** ******* *******
*** **,**** : **** ******** ****** ***** *** ******* **** *********** **** ******* ******* ** ********* & ************* (******* '***, '***, '***, '***).
***** *,**** : ****** ***** * **** ******* **** ** ******** ***** ** ******** ******** ** *** ****.
*** *, **** : ****** *** **** ******* * ********** *** *** ******* ****** ********** ********** *** ******* **** ******* ********* ********** ******** ** *******, ******* *** ******. *** ***** ** *** ********** *** *** *****.
*** **, **** : ****** *** ********* ********, ********* ** ***** ****** ***** **** *** ** ******* *******
*** **, **** : ****** ***** * **** ******* ***** ** ******** ***** ** ******** ******** ** ******* ** ***** ***** **** ** **** ******* '*** (*** *, ****), '***. (**** *, ****).
*** *, **** : ****** *** **** ******* **** ** ********* ** ****** *** ******* ****** ********** ********** *** ************* ******* **** ******* ******* *** *******.
*** **, **** : ********** *** ******* **** ***** ***** *** ***** ** ********** *** *** *****.
*** **, **** : ******** *** ********* ********, ********* ** ***** ******** ***** **** *** ** ******* *******
*** *, **** : ********* *** ********, ********* ** ***** ********* ***** * **** ** *** ******* *******, *** ** *** *** *********
*** *, **** : ****** **** ****, **** **** ****** ******* ******* ** **** ****
*** *, **** : ***** *** ********, ********* ** ***** ***** ***** **** *** ** ******* *******

Atripla - (600mg; 200mg; 300mg Tablet oral)

Executive Summary

Patent Status

Launch Timelines and Competition

Chronology Of Events

ParaIV Advanced Search

Please contact contact@researchdelta.com to get more details.

Headquarters

Products & Services

Quick Links